These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 8195713)

  • 1. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.
    Skorski T; Kanakaraj P; Ku DH; Nieborowska-Skorska M; Canaani E; Zon G; Perussia B; Calabretta B
    J Exp Med; 1994 Jun; 179(6):1855-65. PubMed ID: 8195713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway.
    Tauchi T; Boswell HS; Leibowitz D; Broxmeyer HE
    J Exp Med; 1994 Jan; 179(1):167-75. PubMed ID: 7505797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.
    Druker B; Okuda K; Matulonis U; Salgia R; Roberts T; Griffin JD
    Blood; 1992 May; 79(9):2215-20. PubMed ID: 1571536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
    Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p120 GAP requirement in normal and malignant human hematopoiesis.
    Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak M; Szczylik C; Zon G; Arlinghaus RB; Gewirtz A; Perussia B; Calabretta B
    J Exp Med; 1993 Dec; 178(6):1923-33. PubMed ID: 8245773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
    Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
    Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine phosphorylated proteins in chronic myelogenous leukemia.
    Frackelton AR; Kumar PS; Kannan B; Clark JW
    Leuk Lymphoma; 1993; 11 Suppl 1():125-9. PubMed ID: 7504542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis.
    Skorski T; Nieborowska-Skorska M; Szczylik C; Kanakaraj P; Perrotti D; Zon G; Gewirtz A; Perussia B; Calabretta B
    Cancer Res; 1995 Jun; 55(11):2275-8. PubMed ID: 7757976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
    Carlesso N; Griffin JD; Druker BJ
    Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
    Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells.
    Hallek M; Danhauser-Riedl S; Herbst R; Warmuth M; Winkler A; Kolb HJ; Druker B; Griffin JD; Emmerich B; Ullrich A
    Br J Haematol; 1996 Jul; 94(1):5-16. PubMed ID: 8757502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
    Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
    J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
    Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
    Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
    Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
    Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
    Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
    Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Munthe HA; Verfaillie CM
    Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Philadelphia chromosome-positive chronic myelogenous leukemia with deleted fusion of BCR and ABL genes.
    Ohyashiki K; Ohyashiki JH; Iwabuchi H; Tauchi T; Iwabuchi A; Toyama K
    Jpn J Cancer Res; 1990 Jan; 81(1):35-42. PubMed ID: 2157692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
    Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
    Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.